Skip to main content
Erschienen in: Obesity Surgery 7/2011

01.07.2011 | Clinical Research

Effects of Sleeve Gastrectomy and Medical Treatment for Obesity on Glucagon-like Peptide 1 Levels and Glucose Homeostasis in Non-diabetic Subjects

verfasst von: Juan Patricio Valderas, Veronica Irribarra, Lorena Rubio, Camilo Boza, Manuel Escalona, Yessica Liberona, Andrea Matamala, Alberto Maiz

Erschienen in: Obesity Surgery | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The effects of medical and surgical treatments for obesity on glucose metabolism and glucagon-like peptide 1 (GLP-1) levels independent of weight loss remain unclear. This study aims to assess plasma glucose levels, insulin sensitivity and secretion, and GLP-1 levels before and after sleeve gastrectomy (SG) or medical treatment (MED) for obesity.

Methods

This study is a prospective, controlled, non-randomised study. Two groups of non-diabetic obese patients with similar BMIs, including a SG group (BMI, 35.5 ± 0.9 kg/m2; n = 6) and a MED group (BMI, 37.7 ± 1.9 kg/m2; n = 6) and a group of lean subjects (BMI, 21.7 ± 0.7 kg/m2; n = 8).

Results

Plasma glucose, insulin, and total GLP-1 levels at fasting and after the intake of a standard liquid meal at baseline and at 2 months post-intervention. At baseline, total GLP-1 levels were similar, but obese patients had lower insulin sensitivity and higher insulin secretion than lean subjects. At 2 months post-intervention, SG and MED patients achieved similar weight loss (14.4 ± 0.8%, 15.3 ± 0.9%, respectively). Insulin sensitivity increased in SG and MED patients; however, postprandial insulin secretion decreased after MED, but not after SG. The incremental area under the curve of GLP-1 increased after SG (P = 0.04), but not after MED.

Conclusions

Weight loss by medical or surgical treatment improved insulin sensitivity. However, only MED corrected the hyperinsulinemic postprandial state associated to obesity. Postprandial GLP-1 levels increased significantly after SG without duodenal exclusion, which may explain why insulin secretion did not decrease following this surgery.
Literatur
1.
Zurück zum Zitat Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.CrossRef Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.CrossRef
2.
3.
Zurück zum Zitat DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia. 2010;53:1270–87.PubMedCrossRef DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia. 2010;53:1270–87.PubMedCrossRef
4.
Zurück zum Zitat Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317–35.PubMedCrossRef Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317–35.PubMedCrossRef
5.
Zurück zum Zitat Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMedCrossRef Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMedCrossRef
6.
Zurück zum Zitat Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef
7.
Zurück zum Zitat Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15:145–54.PubMedCrossRef Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15:145–54.PubMedCrossRef
8.
Zurück zum Zitat Gagner M, Deitel M, Kalberer TL, et al. The Second International Consensus Summit for sleeve gastrectomy, March 19–21, 2009. Surg Obes Relat Dis. 2009;5:476–85.PubMedCrossRef Gagner M, Deitel M, Kalberer TL, et al. The Second International Consensus Summit for sleeve gastrectomy, March 19–21, 2009. Surg Obes Relat Dis. 2009;5:476–85.PubMedCrossRef
9.
Zurück zum Zitat Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–41.PubMedCrossRef Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–41.PubMedCrossRef
10.
11.
Zurück zum Zitat Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab. 2009;23:425–32.PubMedCrossRef Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab. 2009;23:425–32.PubMedCrossRef
12.
13.
Zurück zum Zitat Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19:217–29.PubMedCrossRef Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19:217–29.PubMedCrossRef
14.
Zurück zum Zitat Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069–75.PubMedCrossRef Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069–75.PubMedCrossRef
15.
Zurück zum Zitat van Delft J, Uttenthal O, Koch C, et al. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. Metabolism. 1999;48:41–6.PubMedCrossRef van Delft J, Uttenthal O, Koch C, et al. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. Metabolism. 1999;48:41–6.PubMedCrossRef
16.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistence and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistence and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
17.
Zurück zum Zitat Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care. 1999;22:1462–70.CrossRef Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care. 1999;22:1462–70.CrossRef
18.
Zurück zum Zitat Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diab Care. 2000;23:295–301.CrossRef Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diab Care. 2000;23:295–301.CrossRef
19.
Zurück zum Zitat Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008;152:618–21.PubMedCrossRef Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008;152:618–21.PubMedCrossRef
20.
Zurück zum Zitat Maki KC, McKenney JM, Farmer MV, et al. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. Nutr J. 2009;28:1–10. Maki KC, McKenney JM, Farmer MV, et al. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. Nutr J. 2009;28:1–10.
21.
Zurück zum Zitat Navaneethan SD, Kelly KR, Sabbagh F, et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010;20:308–15.PubMedCrossRef Navaneethan SD, Kelly KR, Sabbagh F, et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010;20:308–15.PubMedCrossRef
22.
Zurück zum Zitat Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004;53:S26–33.PubMedCrossRef Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004;53:S26–33.PubMedCrossRef
23.
Zurück zum Zitat Pereira JA, Claro BM, Pareja JC, et al. Restored insulin inhibition on insulin secretion in nondiabetic severely obese patients after weight loss induced by bariatric surgery. Int J Obes Relat Metab Disord. 2003;27:463–8.PubMedCrossRef Pereira JA, Claro BM, Pareja JC, et al. Restored insulin inhibition on insulin secretion in nondiabetic severely obese patients after weight loss induced by bariatric surgery. Int J Obes Relat Metab Disord. 2003;27:463–8.PubMedCrossRef
24.
Zurück zum Zitat Jimenez J, Zuniga-Guajardo S, Zinman B, et al. Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab. 1987;64:661–8.PubMedCrossRef Jimenez J, Zuniga-Guajardo S, Zinman B, et al. Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab. 1987;64:661–8.PubMedCrossRef
25.
Zurück zum Zitat Letiexhe MR, Scheen AJ, et al. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord. 1994;18:295–300.PubMed Letiexhe MR, Scheen AJ, et al. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord. 1994;18:295–300.PubMed
26.
Zurück zum Zitat Morínigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 2006;16:1594–601.PubMedCrossRef Morínigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 2006;16:1594–601.PubMedCrossRef
27.
Zurück zum Zitat Camastra S, Manco M, Mari A, et al. Beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes. 2005;54:2382–9.PubMedCrossRef Camastra S, Manco M, Mari A, et al. Beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes. 2005;54:2382–9.PubMedCrossRef
28.
Zurück zum Zitat Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care. 2007;30:1709–16.CrossRef Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care. 2007;30:1709–16.CrossRef
29.
Zurück zum Zitat Horowitz M, Cook DJ, Collins PJ, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg. 1982;69:655–7.PubMedCrossRef Horowitz M, Cook DJ, Collins PJ, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg. 1982;69:655–7.PubMedCrossRef
30.
Zurück zum Zitat Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007;17:57–62.PubMedCrossRef Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007;17:57–62.PubMedCrossRef
31.
Zurück zum Zitat Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–8.PubMed Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–8.PubMed
32.
Zurück zum Zitat Langer FB, Reza Hoda MA, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005;15:1024–9.PubMedCrossRef Langer FB, Reza Hoda MA, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005;15:1024–9.PubMedCrossRef
33.
Zurück zum Zitat Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083–6.PubMedCrossRef Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083–6.PubMedCrossRef
34.
Zurück zum Zitat Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.PubMedCrossRef Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.PubMedCrossRef
35.
Zurück zum Zitat Guldstrand M, Ahrén B, Näslund E, et al. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. Diabetes Obes Metab. 2009;1:1027–33.CrossRef Guldstrand M, Ahrén B, Näslund E, et al. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. Diabetes Obes Metab. 2009;1:1027–33.CrossRef
36.
Zurück zum Zitat Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44–54.PubMedCrossRef Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44–54.PubMedCrossRef
37.
Zurück zum Zitat Christensen M, Knop FK, Vilsbøll T, et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regul Pept. 2010;163:96–101.PubMedCrossRef Christensen M, Knop FK, Vilsbøll T, et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regul Pept. 2010;163:96–101.PubMedCrossRef
38.
Zurück zum Zitat Hansen L, Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno–ileal loop? Regul Pept. 2002;110:39–45.PubMedCrossRef Hansen L, Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno–ileal loop? Regul Pept. 2002;110:39–45.PubMedCrossRef
39.
Zurück zum Zitat Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165–74.PubMed Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165–74.PubMed
Metadaten
Titel
Effects of Sleeve Gastrectomy and Medical Treatment for Obesity on Glucagon-like Peptide 1 Levels and Glucose Homeostasis in Non-diabetic Subjects
verfasst von
Juan Patricio Valderas
Veronica Irribarra
Lorena Rubio
Camilo Boza
Manuel Escalona
Yessica Liberona
Andrea Matamala
Alberto Maiz
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 7/2011
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0375-4

Weitere Artikel der Ausgabe 7/2011

Obesity Surgery 7/2011 Zur Ausgabe

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.